Germline mutations in the tumor-suppressor gene PTEN predispose to heritable breast cancer. The transcription factor peroxisome proliferator-activated receptor-gamma (PPARg) has also been implicated as a tumor suppressor pertinent to a range of neoplasias, including breast cancer. We previously demonstrated that lovastatin may signal through PPARg and directly upregulate PTEN expression at the transcriptional level. In our current study, we show that simvastatin, pravastatin and fluvastatin can induce PTEN expression in a dosedependent manner. This resulted from an increase in PTEN mRNA indicating transcriptional upregulation. In addition, we observed, for the first time, that upregulation of sterol response element-binding protein (SREBP), known to induce PPARg expression, can increase PTEN expression. Using reporter assays, we observed that both the statins and SREBP could specifically induce PPARg-mediated transcription. However, the statins do not appear to signal through SREBP. Furthermore, our results indicate that SREBP utilizes PPARg's transcriptional activity to induce PTEN transcription, whereas the statins signal through PPARg's protein activity to upregulate PTEN expression. Overall, our observations suggest that statins signal through another transcription factor, in a PPARg-dependent manner, which in turn induces PTEN transcription. We, therefore, studied the full-length PTEN promoter through serial deletion reporter assays and electromobility shift assays and identified a region between 2854 and 2791 that binds an as-yet-unidentified transcription factor, through which the statins induce PTEN expression. Since PTEN is constitutively active, our data indicate it may be worthwhile to examine statin and SREBP stimulation as mechanisms to increase PTEN expression for therapeutic and preventative strategies in cancer, diabetes mellitus and cardiovascular disease.
INTRODUCTION
Germline mutations in PTEN, a tumor-suppressor gene on 10q23, occur in 85% of patients with the autosomal-dominant Cowden syndrome [CS (MIM 158350)] (1-3). This syndrome is reported to affect approximately one in 200 000 individuals. However, because CS is difficult to diagnose, this is generally thought to be an underestimate (4) . Patients diagnosed with CS have a 25-50% lifetime risk of developing female breast cancer compared with 13% in the general population (5, 6) . In addition to breast cancer, CS patients also have thyroid neoplasias, mucocutaneous lesions, fibrocystic breast disease, uterine leiomyoma and macrocephaly (6, 7) . Germline PTEN mutations are also associated with subsets of patients with developmental disorders. Approximately 65% of patients with Bannayan -Riley-Ravalcaba syndrome (MIM 153480), 20% of those with Proteus syndrome (MIM 176920), 50% of a Proteus-like syndrome (4) and 10-20% of autism spectrum disorder with macrocephaly (3, 8, 9) share germline PTEN mutations as an etiology and have all been classified as PTEN hamartoma tumor syndromes (2) . Furthermore, somatic alterations in PTEN, whether by genetic or epigenetic mechanisms, play some role in the pathogenesis of a broad range of solid tumors, such as sporadic carcinomas of the breast, thyroid, endometrium and colon (4) .
PTEN's protein product, PTEN, is a dual-specificity phosphatase with both lipid and protein phosphatase activities (10) , which elicits cell cycle arrest and apoptosis. PTEN is a constitutively expressed protein; therefore, regulation of its protein levels through transcription is key to its function. In recent years, transcriptional regulation of PTEN has been researched more extensively; however, there is still much to be understood. Several groups have shown that PTEN transcription may be regulated by early growth response-1 (Egr-1) (11), p53 (12) , Sp1 (13) , NF-kB (14) , CBF-1 (15), USF1 (16) and c-Jun (17) . In addition, in 2001, two putative binding sites for the transcription factor peroxisome proliferator-activated receptor-gamma (PPARg) were identified 10 kb upstream of the minimal promoter region of PTEN (18) ; specific binding of PPARg was later confirmed (19) . Moreover, our laboratory demonstrated that PPARg, through activation by rosiglitazone or lovastatin, induces PTEN transcription and subsequently upregulates PTEN protein levels (20) . These data were the first to suggest that a statin, more specifically lovastatin, signals through PPARg and upregulates PTEN expression.
Statins have long been thought to have some anti-carcinogenic properties, but concrete evidence remains to be lacking. Clinically, statins are used as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, which downregulate cholesterol production through the mevalonate pathway. However, further research shows that this pathway can also regulate other proteins, such as Ras and Rho, that are key to cancer development (21) . Lovastatin (Mevacor), simvastatin (Zocor), pravastatin (Livals) and fluvastatin (Lescol) are commonly prescribed for millions of patients to aid in lowering cholesterol levels for both the primary and secondary prevention of cardiovascular disease (22) . In this study, we investigated whether four statins (simvastatin, pravastatin, fluvastatin and mevastatin), beyond lovastatin, have the ability to act as anti-carcinogenic agents by upregulating PTEN expression through PPARg, similar to lovastatin or via other mechanisms.
RESULTS

Simvastatin, pravastatin and fluvastatin induce PTEN protein expression in a dose-dependent manner
We have recently demonstrated that lovastatin upregulates PTEN expression (20) . To determine whether other statins could upregulate PTEN expression, we stimulated MCF-7 breast cancer cells with four additional statins: simvastatin, pravastatin, fluvastatin and mevastatin. The optimal concentration for increased PTEN expression was determined by performing a dose curve on the basis of their previously established IC 50 s in breast cancer cell lines (23) . MCF-7 cells expressed a basal level of PTEN, which was unchanged when exposed to the ethanol (EtOH) vehicle control ( Fig. 1 ; 0 mM). When MCF-7 cells were stimulated with mevastatin, we did not observe any changes in PTEN expression despite the wide range of doses centered on its IC 50 ( Fig. 1D ; 0 -25 mM). In contrast, simvastatin, pravastatin and fluvastatin induced a dose-dependent increase in PTEN expression after treatment. The greatest increase in PTEN expression occurred at 3, 30 and 18 mM for simvastatin, pravastatin and fluvastatin, respectively (Fig. 1A -C) . Our previous work demonstrated that 3 mM lovastatin could stimulate 1.8-fold induction of PTEN expression. Our current study exhibits a similar induction of PTEN with simvastatin (1.5-fold), pravastatin (1.4-fold) and fluvastatin (1.6-fold).
Statin treatment induces PTEN mRNA expression
Our previous work indicated that lovastatin induces PTEN protein by upregulating PTEN transcription and, subsequently, its mRNA levels (20) . To determine whether simvastatin, pravastatin, fluvastatin and mevastatin stimulation induces PTEN transcription in a similar manner as lovastatin, we examined the levels of PTEN mRNA by reverse transcriptasepolymerase chain reaction (RT-PCR) after treatment. Basal levels of PTEN transcript were observed in unstimulated MCF-7 cells or those treated with EtOH vehicle ( Fig. 2A ; EtOH). In contrast, cells stimulated with 3 mM simvastatin for 48 h had an 1.7-fold increase in PTEN transcript ( Fig. 2A; Sim) . An 1.8-fold induction of PTEN transcript was observed after 30 mM pravastatin stimulation ( Fig. 2A ; Pra). Furthermore, an 1.8-fold induction of PTEN transcript was also observed after stimulation with 18 mM fluvastatin Figure 1 . Simvastatin, pravastatin and fluvastatin induce PTEN protein expression in a dose-dependent manner. Cells were stimulated with simvastatin (A), pravastatin (B), fluvastatin (C) or mevastatin (D) and harvested after 48 h stimulation as indicated. Levels of PTEN and actin were detected by western blot as described in the Materials and Methods section, and relative expression of PTEN plotted against statin concentration (E). Representative blots of three individual experiments are displayed.
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( Fig. 2A; Flu) . The induction rates observed with these statins are very similar to that observed with lovastatin (1.8-fold) (20) . We additionally examined PTEN mRNA levels in MCF-7 cells after stimulation with mevastatin to confirm its inability to induce PTEN expression. As expected, we did not observe an induction of PTEN mRNA after mevastatin treatment ( Fig. 2A ; Mev). These data demonstrate that simvastatin, pravastatin and fluvastatin stimulation induces PTEN transcription.
Statin stimulation induces PPARg-mediated transcription
We previously demonstrated that lovastatin induces PTEN and upregulates PPARg-mediated transcription similar to rosiglitazone, a known synthetic PPARg ligand (20) . To determine whether simvastatin, pravastatin and fluvastatin could regulate PPARg-mediated transcription as well, we utilized a previously described reporter assay system (20, 24) . This reporter assay system takes advantage of the known PPARg response element (PPRE), which has been luciferase-tagged (24 Fig. 2B; DN) . These results indicate that all five statins can both significantly and specifically induce PPARg-mediated transcription. These data were both unexpected and interesting. We observed that lovastatin, simvastatin, pravastatin and fluvastatin induced PTEN expression, whereas mevastatin did not (Fig. 1) . However, the reporter assay results indicate that all five statins can signal though PPARg-mediated transcription. These results were unexpected because our previously published data demonstrated that PPARg protein is necessary to induce PTEN (20) . We initially expected to observe all the statins induce PTEN expression signaling through PPARg-mediated transcription; however, our mevastatin results suggest that this may not be the signaling pathway utilized. It has been previously suggested that statins can signal through sterol response element-binding protein (SREBP); however, the exact mechanisms are still being elucidated (21, 25) . In addition, published data indicate that SREBP can upregulate PPARg protein expression and subsequently induce PPARg-mediated transcription (26) . Therefore, on the basis of our results and these published data, we hypothesized three potential model pathways of PTEN upregulation by statins via SREBP and PPARg (Fig. 3) . In model A, statins signal through SREBP to induce PPARg-mediated transcription, subsequently increasing PTEN expression (Fig. 3A) . However, it is entirely possible that statins may upregulate PPARg-mediated transcription and, therefore, PTEN through a signaling pathway distinct from that of SREBP (Fig. 3B, model B) . Our results from the earlier-mentioned reporter assay may indicate that statins may induce PTEN expression through a signaling pathway that utilizes PPARg activity independent of PPARg's transcriptional activity (Fig. 3C , model C).
Both statins and SREBP can induce PTEN protein expression
As noted earlier, published data suggest that statins upregulate PTEN through PPARg-mediated transcription, and that SREBP may be a mediator ( Fig. 3A) (26) . To test this hypothesis, we utilized N-acetyl-leucyl-leucyl-norleucinal (ALLN), which inhibits SREBP catabolism, thus upregulating its expression and function. MCF-7 cells were treated with lovastatin, simvastatin, pravastatin, fluvastatin or ALLN for 48 h, and whole-cell protein lysates were examined by western blot analysis. Vehicle (EtOH)-treated cells express a basal level of SREBP and PPARg protein ( Our current study indicates that statins can universally induce PTEN expression and suggest that SREBP can as well. Therefore, to establish that the effects we see with statin stimulation are not cell-specific, and that SREBP can induce PTEN expression, we compared our results obtained in MCF-7 ( Fig. 5A, ALLN-DN) . Interestingly, when MCF-7 cells were treated with ALLN in concert with the any of four statins that induced PTEN expression (lovastatin, simvastatin, pravastatin and fluvastatin), we observed an inhibition of luciferase activity compared with ALLN alone. By comparing these results (Fig. 5A) with our previous reporter assay results ( These observations suggest that ALLN-related upregulation of PPARg-mediated transcription may be due to SREBP induction; however, it may also be a result of ALLN's proteasome inhibitor activity. Therefore, to test ALLN's role in PPARg-mediated transcription, we performed a reporter assay (similar to that shown in Fig. 5A ) with MG-132, another proteasome inhibitor (27) . In contrast to ALLN, MG-132 did not produce an induction of PPARg-mediated transcription, indicating that this is not a general proteasome inhibitor phenomenon (data not shown). These data suggest that SREBP induces PPARg protein, resulting in increased PPARg transcriptional activity. In addition, these data provide evidence that statins do not signal through SREBP to induce PTEN expression, thus, excluding model A (Fig. 3A) . Instead, our data suggest that these two signaling pathways appear to antagonize each other.
SREBP, but not the statins, induces PPARg-mediated transcription to increase PTEN protein expression
Our results suggest that statins signal down a pathway separate from SREBP, potentially as illustrated in model B (Fig. 3B) . In addition, SREBP may have the ability to induce PTEN expression through the upregulation of PPARg transcriptional activity although this observation may be artificial. In the aforementioned reporter assay system (Figs 2B and 5A), we added exogenous PPARg protein to observe an increase in PPARg-mediated transcription. However, in our initial western blots (Fig. 1) , we observed an induction of PTEN expression after statin stimulation without the addition of exogenous PPARg. In order to determine whether the statins and SREBP truly signal through PPARg to induce PTEN transcription, we performed a reporter assay in the absence of exogenous PPARg protein. MCF-7 cells were transfected with only the PPRE-Luc vector and subsequently stimulated with the four statins, ALLN or the statin/ALLN combination. 
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Statin stimulation alone presented no induction of PPARgmediated transcription, compared with EtOH, when exogenous PPARg was not added to the system ( Fig. 5B ; bars 1 -5). In contrast, we observed an induction of luciferase activity after ALLN stimulation ( Fig. 5B ; bar 6; 40-fold). Stimulation of MCF-7 cells with ALLN in concert with the statins altered PPARg-mediated transcription compared with ALLN alone, but remained significantly induced over statin treatment alone ( Fig. 5B ; bars 7 -10). These data suggest that statins do not have the ability to induce PPARg-mediated transcription when PPARg protein levels are low, thus suggesting that PPARg's transcriptional activity is not a key 'player' in PTEN induction after statin stimulation. On the basis of these results, model C might be the most accurate representation of statin and SREBP upregulation of PTEN expression (Fig. 3C ).
Rosiglitazone does not inhibit SREBP induction of PPARg-mediated transcription
It has been previously suggested that SREBP has the ability to induce the production of natural PPARg ligands (26) . This indicates that SREBP's ability to induce both PPARg protein and its ligand may be a mechanism for the increase in PPARg's transcriptional activity. Our data demonstrate that statins can antagonize this pathway, potentially by interfering with PPARg's natural ligands. To test this hypothesis, we utilized rosiglitazone, a synthetic but documented PPARg ligand. We would expect rosiglitazone to signal down the same pathway as the natural PPARg ligands and to induce PPARg-mediated transcription, although not hindering ALLN's induction. Therefore, we stimulated MCF-7 cells with rosiglitazone, ALLN or the combination of rosiglitazone and ALLN and analyzed PPARg's transcriptional activity. Rosiglitazone induced 120-fold increase in luciferase activity, whereas ALLN induced 160-fold increase in luciferase activity over EtOH-treated cells (Fig. 6) . Interestingly, the combination of rosiglitazone and ALLN (150-fold) did not inhibit ALLN signaling as previously observed with the four statins (Fig. 5A ). This suggests that statins hinder natural PPARg ligand signaling. In addition, these data confirm that statins do not induce PPARg-mediated transcription, but rather, regulate a separate PPARg protein activity to induce PTEN expression as illustrated in model C (Fig. 3C ).
Statins upregulate PTEN transcription through an unknown transcription factor located between 2854 and 2791
Our results, consistent with our proposed model C (Fig. 3C) , show that statin stimulation increases PTEN transcription in a PPARg transcriptional activation-independent mechanism, suggesting the involvement of another transcription factor(s).
To examine this in greater detail, we performed transcriptional reporter assays using serial deletions of the PTEN promoter. Seven PTEN promoter constructs were cloned into pGL3-Basic vectors: 21334 to 0, 21158 to 0, 21026 to 0, 2893 to 0, 2601 to 0, 2453 to 0 and 2203 to 0 and subsequently transfected into MCF-7 cells. Twelve hours after transfection, MCF-7 cells were treated with either EtOH or one of the statins. Luciferase activity was measured and the results indicated that only one construct, containing 2893 to 0, could significantly induce PTEN transcription (3.5-fold) over EtOH-treated cells (data not shown). Using this as a starting point, we constructed six more serial deletion vectors (Fig. 7A ). These vectors were transfected into MCF-7 cells followed by statin treatment. Only the construct containing the PTEN promoter region between 2893 and 2601 could be significantly induced after lovastatin (2.5-fold), simvastatin (6.5-fold), pravastatin (6.5-fold) and fluvastatin (4.0-fold) stimulation (Fig. 7B) .
Our PTEN promoter reporter assays demonstrated that statin stimulation induced transcription from a site between 2893 and 2601, which is interesting since there are no known transcription factors that bind to this region. To more accurately define the nucleotides of interest within this region, we utilized three different PTEN promoter probes. As expected, no retarded bands were observed during electromobility shift assay (EMSA) when nuclear protein was not added to the system (Ng). Protein binding (Bd) was observed utilizing the 2893 to 2601 probe (Fig. 7C, 893 -601) , whereas the addition of a nonspecific competitor (Nn) did not alter the binding and a specific competitor (Sp) did. This probe was subsequently divided into two additional probes: 2893 to 2755 and 2769 to 2608. The 2893 to 2755 probe demonstrated specific protein binding (Fig. 7C, 893-755) , whereas the more 3 0 probe did not reveal any protein binding (Fig. 7C, 769-609) . Interestingly, our laboratory, while studying patient promoter variants that affect protein translation, identified this region as a target for the binding of a yet-unidentified transcription factor(s) (28) . In order to further dissect out this region of binding, we constructed five more serial deletion probes. Figure 7D shows specific protein binding for three of the five probes, with the smallest region of interest on the PTEN promoter that the statins regulate being between 2854 and 2791. Overall, therefore, our data suggest that statins upregulate PTEN transcription by regulating PPARg protein activity, which subsequently induces an as yet-unknown transcription factor that binds to the PTEN promoter between 2854 and 2791. In addition, we were also able to demonstrate, for the first time, that SREBP can also induce PTEN transcription through upregulation of PPARg-mediated transcription.
DISCUSSION
PTEN is a constitutively active dual specificity phosphatase tumor suppressor. As such, regulation of activity is determined by protein level. We have demonstrated that statins, more specifically lovastatin, simvastatin, pravastatin and fluvastatin, induce PTEN transcription through regulating PPARg protein 
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Other groups have shown that statins can increase PPARg mRNA and subsequently its protein expression (29, 30) . Our current study indicates that statins may secondarily induce PPARg transcriptional activity independent of PTEN regulation. We demonstrated that the statins induced PTEN expression in the presence of endogenous PPARg protein levels ( Figs 1 and 2A) ; however, additional exogenous PPARg was required for the statins to induce PPARg's transcriptional activity (Fig. 2B) . The addition of exogenous PPARg was essential because MCF-7 cells express low levels of PPARg (Fig. 4A) . This indicated that PPARg protein is the limiting factor in statin regulation of its transcriptional activity, but not for the upregulation of PTEN expression. Moreover, we established that in the presence of WT-PPARg, but not DN-PPARg, an induction of PPARgmediated transcription could be observed after statin stimulation (Fig. 2B) . This further indicates that the statins' ability to induce PPARg transcriptional activity is a specific effect; however, it is also clear from our work that it is not the primary pathway for PTEN induction.
We initially proposed that statins induced PPARg-mediated transcription to increase PTEN levels; however, our data demonstrate that this hypothesis was incorrect. These results were unexpected because we previously demonstrated that PPARg protein expression is necessary in order to observe the induction of PTEN expression (20) . Another protein that the statins have been connected with and is involved in regulating lipid metabolism is SREBP (25) , which has been shown to be involved in PPARg's protein production and transcriptional activity (26) . This raises the possibility that statins, 1 -4) , 2893 to 2755 (lanes 5-8) and 2769 to 2608 (lanes 9 -12) were radiolabeled and used as probes for EMSA analysis. Each promoter probe was either incubated in the presence (Bd) or absence (Ng) of nuclear protein and subsequently competed with a non-specific (Nn) or specific (Sp) competitor. A representative blot from three individual experiments is displayed. (D) WT PTEN promoters 2893 to 2791 (lanes 1 -4) , 2893 to 2834 (lanes 5 -8), 2854 to 2791 (lanes 9-12), 2854 to 2755 (lanes 13-16) and 2811 to 2755 (lanes [17] [18] [19] [20] were radiolabeled and used as probes for EMSA analysis. Nuclear protein was either not incubated with the probe (Ng) or incubated with the probe (Bd) to test binding. Competition assays were performed with a non-specific competitor (Nn) and unlabeled WT promoter probe (Sp). A representative blot from three individual experiments is displayed.
PPARg and SREBP may all play a role in modulating PTEN expression. Our results indicate that both the statins and SREBP can signal through PPARg; however, they do so differently and independent of each other. Here, SREBP principally utilized PPARg's transcriptional activity, whereas statins primarily signal through a pathway independent of PPARg's transcriptional activity. These results are in agreement with Ravid et al.'s (31) study which demonstrated that ALLN inhibited HMG-CoA reductase degradation. The combination of statin treatment with increased SREBP activity actually antagonized the two pathways (Fig. 5B) . In contrast, Mascaro et al. (32) observed a fluvastatin/ALLN synergistic effect on transcriptional activity in CHO cells. Our data indicate that SREBP has the ability to induce PTEN expression (Fig. 4A) , suggesting that its upregulation of PPARg-mediated transcription induces PTEN transcription. On the basis of these results, SREBP agonists may aid patients who demonstrate a decrease in PTEN but do not have an isolated PTEN mutation in the open reading frame; unfortunately, a clinically relevant SREBP agonist has yet to be established. However, one needs to be conscious of the idea that the combination of statins and an SREBP agonist may actually hinder the effect of each individual treatment.
Overall, our data strongly suggest that statins regulate a transcription factor(s), besides PPARg, to induce PTEN transcription. We have demonstrated that lovastatin, simvastatin, pravastatin and fluvastatin upregulate PTEN transcription in the context of the PTEN promoter defined by a region flanking nucleotides 2893 and 2601 (Fig. 7B) and that an unknown transcription factor(s) bind(s) between 2854 and 2791 (Fig. 7D) . Only two transcription factors are predicted by multiple prediction software programs to bind at this region: Sp1 [TESS (33) and Alibaba (34) ] and c-Myb [TESS and TFSEARCH (35) ]. Sp1 is currently thought to be a putative PTEN transcription factor, due to the full-length PTEN promoter being very GC rich; however, empiric research has yet to concretely show that it binds to any particular region of the promoter or has the ability to regulate its transcription (3, 27) . c-Myb has been shown to be upregulated within tumors when PTEN expression was decreased (36) , indicating that it may be acting as a PTEN transcriptional repressor; however, the pathway connecting the two has yet to be determined. Thus, both Sp1 and c-Myb may be postulated to be regulators of PTEN expression; however, more in-depth studies are necessary to determine the identity of this novel PTEN transcription factor and are beyond the scope of this article.
Our data reinforce the importance and benefit that agonists which upregulate PTEN transcription may be useful to a subset of breast cancer patients. This suggests that a therapeutic tool that can regulate PTEN's transcription would be highly effective within the subset of patients who have an identified nucleotide alteration within the PTEN promoter or in patients in whom a PTEN mutation has yet to be identified. This approach would also be useful where hemizygous deletions occur, as in sporadic neoplasias, in increasing PTEN protein levels. This study indicates that lovastatin, simvastatin, pravastatin and fluvastatin as well as an SREBP agonist would be germane to this cohort of patients. However, despite these encouraging results, we must be aware that these potential therapies may theoretically harm patients with germline intragenic PTEN mutations or those with neoplasias with somatic intragenic mutations by raising levels of mutant, as well as wildtype, protein.
MATERIALS AND METHODS
Materials
Fluvastatin, mevastatin, lovastatin, pravastatin and simvastatin were obtained from Cayman Chemical (Ann Arbor, MI, USA). ALLN was purchased from Biomol International (Plymouth Meeting, PA, USA). Antibodies were obtained from Cascade Bioscience, Waltham, MA, USA (PTEN 6H2.1), Sigma-Aldrich (Actin) and Cell Signaling (PPARg and SREBP1). Cell culture media was obtained from the Cleveland Clinic Media Core. M-PER mammalian protein extraction reagent was obtained from Pierce Biotechnology, Inc. (Rockford, IL, USA). All other reagents were purchased from standard commercial sources.
Cell culture and stimulation
The MCF-7 cell line was maintained at 378C with 5% CO 2 in DMEM containing 10% FBS and 100 U/ml each penicillin and streptomycin. MDA-MB-231, MDA-MD-435 and T47D breast cancer cell lines were maintained at 378C with 5% CO 2 in RPMI containing 10% FBS and 100 U/ml each penicillin and streptomycin. Cells were plated at 1.0 Â 10 8 24 h prior to the treatment. After 24 h, cells were treated as indicated in the Results section and in figure legends. Following treatments, cells were incubated for an additional 48 h prior to harvesting.
Protein extraction
MCF-7, MDA-MB-231, MDA-MB-435 and T47D cells were plated and stimulated as described earlier. At the time of harvest, media was removed and the cells were washed with PBS. Cells were then harvested into M-PER lysis buffer containing phenylmethanesulphonyl fluoride (0.75 mg/ml), benzamidine hydrochloride (0.5 mg/ml), leupeptin (2 mg/ml), aprotinin (2 mg/ml), pepstatin (2 mg/ml), b-glycerophosphate (10 mM), NaOV (0.2 mM) and NaF (25 mM). Cells were incubated at room temperature with lysis buffer for 1 min before harvesting by scraping. Samples were then centrifuged at 16 000g for 10 min at 48C to remove cellular debris. The resulting supernatant was stored at 2808C. Protein concentration was determined using the bicotinic method (37) using BSA as a standard.
Western blot
Proteins (30 mg) were prepared by the Laemmli method (38), then separated on a 10% SDS -PAGE gel and electrophoretically transferred onto nitrocellulose. Equal protein loading between conditions was confirmed by staining with Ponceau S solution. Non-specific binding was blocked by incubating the nitrocellulose blots with 5% milk in TBS-T (100 mM Tris, pH 7.0, 1 M NaCl, 1% Tween-20) for 1 h at room temperature. Blots were then incubated with the primary antibody (1:1000 in 3% BSA) for 2 h at room temperature. Following the primary incubation, the blots were washed with TBS-T for 1 h with frequent changes of buffer. Blots were then incubated with the appropriate secondary antibody conjugated to horseradish peroxidase (Promega, Madison, WI, USA) (1:2500 dilution in 5% milk) overnight at 48C and washed with TBS-T for 1 h. Protein bands were visualized using enhanced chemiluminescence as described by the manufacturer (Amersham Pharmacia Corp., Piscataway, NJ, USA). The resultant films were then quantified using NIH-Imager densitometry software.
Reverse transcriptase -polymerase chain reaction MCF-7 cells were stimulated as described earlier. After stimulation, cells were released by trypsin treatment and subsequently washed three times with PBS through centrifugation. Total RNA was extracted from cells, following the Gentra Versagene RNA Purification System Protocol (Minneapolis, MN, USA) and then converted to cDNA by Superscript II reverse transcriptase after DNase treatment. The resultant cDNA was subjected to multiplex PCR amplification using primers specific to PTEN exon 3 and exon 5 (F: 5 0 TGGATTCAAAGCATAAAAACCA 3 0 ; R: 5 0 AAAAGGATATTGTGCAACTCTGC 3 0 ) and b-actin (Quantum RNA b-actin, Ambion Inc., Austin, TX, USA). Primers were allowed to anneal at 558C for 28 cycles. The products from the PCR reactions were run on a 1% agarose gel containing ethidum bromide and visualized under a UV light.
Reporter assay
Plasmids were co-transfected into six-well cultures of MCF-7 cells with 3 ml/well of FuGene (Roche). Each well was co-transfected with 500 ng of the reporter plasmid PPRETK-LUC, 50 ng Renilla luciferase control plasmid and 100 ng of receptor expression vector (pcDNA3, WT PPARg1 or L468A/E471A PPARg1). Each plasmid has previously been described (20, 24) . After 12 h, cells were stimulated with EtOH, 3 mM lovastatin, 3 mM simvastatin, 30 mM pravastatin, 18 mM fluvastatin or 10 mM mevastatin for 48 h.
PTEN promoter was PCR-amplified from normal genomic DNA and subsequently cloned into a TOPO-TA vector. DNA was PCR-amplified using 558C as the annealing temperature for 30 cycles. All PCR amplification products were verified by direct DNA sequencing (ABI 3730xl DNA analyzer), and positive clones were subcloned into a pGL3.1-Basic vector (Promega). To determine luciferase activity, six-well plates were co-transfected with 1 mg/well of a pGL3-PTEN construct and 50 ng/well Renilla luciferase control plasmid with 3 ml/well of FuGene. After 12 h, cells were stimulated with EtOH, 3 mM lovastatin, 3 mM simvastatin, 30 mM pravastatin or 18 mM fluvastatin for 48 h. Cells were harvested with 1Â passive luciferase lysis buffer (dual-luciferase reporter assay system, Promega) and analyzed on a luminometer (LMax 11384, Molecular Devices) using Renilla luciferase as an internal transfection control.
Electromobility shift assay
PTEN promoter sequence was isolated through PCR amplification from normal genomic DNA. The DNA was PCR-amplified with 30 cycles at the annealing temperature of 558C in 20 ml reactions using HotStar and Q Solution (Qiagen). Each of these products was radiolabeled with 32 P-gATP via T4 kinase. To examine DNA -protein interaction, 1 ng of radiolabeled probe was incubated with 2 mg of either untreated or statin-treated nuclear protein extract for 20 min at room temperature with binding buffer containing 10 mM HEPES (pH 7.5), 2.5 mM MgCl 2 , 50 mM NaCl, 0.5 mM DTT, 4% glycerol, 1 mg/ml BSA and 2 mg poly dI/dC. Unlabeled probe in 5Â molar excess was used as the specific competitor, whereas a random oligonucleotide sequence was used as the non-specific competitor. DNA -protein complexes were resolved on a 4% non-denaturing PAGE gel at 150 V for 3.5 h at 48C and visualized using a Phospho-Imager (Amersham Biosciences, Piscataway, NJ, USA).
